Revised SPC: Xermelo (telotristat ethyl) 250 mg film-coated tablets

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
29 November 2019

Abstract

SPC has strengthened warnings on risk of depressive disorders and has included the following adverse events; depression/depressed mood (common), nausea (very common) and intestinal obstruction (uncommon).